Life Sciences

  • February 06, 2026

    Insulet Gets $14.9M Fee Award For Trade Secret Trial Win

    A Massachusetts federal judge awarded Insulet Corp.'s attorneys almost $15 million for their $452 million jury trial victory in a trade secrets dispute that was later reduced to $59.4 million, but the fees Goodwin Procter LLP netted were significantly less than the nearly $25 million it requested.

  • February 06, 2026

    FLSA Does Not Bar Claim Waivers, Wash. Judge Says

    The Fair Labor Standards Act does not categorically bar a contract's release of an employee's claims, a Washington federal judge ruled, finding that a former pharmaceutical manufacturing company worker's severance agreement that included a general release of claims precludes his wage suit.

  • February 06, 2026

    HHS Ends 340B Drug Rebate Pilot After Legal Challenge

    The U.S. Department of Health and Human Services has ended a proposed rebate program that would have altered how hospitals receive payments for participating in the federal 340B drug discount program, which provides discounted prescription drugs for low-income Americans, after facing a lawsuit from a major hospital association.

  • February 05, 2026

    NYAG's Insider Trading Case A Power Grab, Judge Told

    The former CEO of healthcare contractor Emergent BioSolutions Inc. has removed to federal court New York Attorney General Letitia James' insider trading case against him, alleging James is trying to expand her office's power through claims that concern questions of federal law.

  • February 05, 2026

    Full Fed. Circ. Won't Rethink Heart Monitor Patent Claim Ax

    The full Federal Circuit won't rethink a panel's refusal to revive claims in a wireless heart rate monitor patent owned by Finnish sports tech company Polar Electro Oy that a lower court found were invalid.

  • February 05, 2026

    Judge Affirms Health Cos.' Sanctions For Witness Omission

    An Illinois federal judge rejected a "vague and unsupported" bid by a home healthcare company accused of violating federal kickback laws to reconsider sanctions she ordered for failing to disclose witnesses, saying the motion "wastes everyone's time" and scolding the defendants for "impugning the character and professionalism of an able magistrate judge."

  • February 05, 2026

    David Protein Gets Ingredient Supply Antitrust Claims Tossed

    A New York federal court dismissed a lawsuit from several low-calorie food producers accusing protein bar-maker David Protein of refusing to sell them a fat replacement ingredient after it purchased the ingredient's only supplier.

  • February 05, 2026

    Patent Co., AI Research Firm Join Forces In $150M Deal

    Patent monetization venture SIM IP has announced a merger valued at $150 million with artificial intelligence research firm Garden Intel, a deal the companies said would create a first-of-its-kind platform.

  • February 05, 2026

    Novo Threatens Hims & Hers With Suit Over GLP-1 'Knockoff'

    Novo Nordisk said in a Thursday announcement it plans to take legal action against Hims & Hers Health Inc. after the telehealth company revealed a "knockoff" version of Novo's popular weight loss drug Wegovy earlier in the day. 

  • February 05, 2026

    Medtronic Hit With $382M Antitrust Verdict Over Bundling

    A California federal jury on Thursday ordered Medtronic to pay nearly $382 million to business rival Applied Medical for antitrust violations, finding the medical device giant illegally used its monopoly power to crush competition in the market for a type of surgical instrument called an advanced bipolar device.

  • February 05, 2026

    Yale Health System Seeks $4.1M Coverage For Transplant

    A Liberty Mutual unit breached a stop-loss insurance policy by denying Yale University's health system $4.1 million in coverage for a plan member's bone marrow transplant, the system told a Connecticut federal court.

  • February 05, 2026

    Trump Admin Finalizes Rule Facilitating Federal Worker Firings

    The Trump administration Thursday announced a final rule to create a new category of federal workers who would have fewer job protections and be easier to fire, implementing an executive order from early last year that could affect 50,000 employees at federal agencies.

  • February 05, 2026

    Covington, Davis Polk Lead Eikon's Upsized $381M IPO

    Oncology-focused biopharmaceutical company Eikon Therapeutics began trading publicly Thursday after raising $381 million in its upsized initial public offering.

  • February 04, 2026

    Ropes Leads Hair-Loss Firm Veradermics' Upsized $256M IPO

    Hair loss drug developer Veradermics Inc. began trading Wednesday after raising $256 million in an upsized initial public offering, with Ropes & Gray LLP representing the company and Cooley LLP representing the underwriters.

  • February 04, 2026

    'Careless Or Disingenuous': Judge Rips CareFirst Rethink Bid

    A Virginia federal judge Wednesday refused to reconsider an order reversing course and throwing out key claims in CareFirst's suit against Johnson & Johnson over the immunosuppressive drug Stelara, calling CareFirst's arguments for doing so "either careless or disingenuous."

  • February 04, 2026

    Medtronic Owes $381M For Antitrust 'War Games,' Jury Told

    An attorney for Applied Medical told a California federal jury Wednesday during closing arguments in an antitrust trial against Medtronic that internal documents from the medical device giant show it played illegal "war games" against his client and should pay up to $381 million. 

  • February 04, 2026

    Fed. Circ. Leans Toward Vacating $12.7M Copyright Award

    The Federal Circuit appeared likely to vacate a $12.7 million copyright infringement award against the federal government on Wednesday, pressing attorneys for a software developer and the government to answer what instructions should be given to the claims court on remand.

  • February 04, 2026

    Class Attys In Del. Northwest Biotherapeutics Praise Deal

    Delaware Chancery Court has lined up a March 16 settlement hearing for a four-year stockholder lawsuit alleging insiders of Northwest Biotherapeutics Inc. received $40 million in stock awards, with proposals including a call for the company to forfeit nearly 22.9 million stock options and it receiving $2.25 million.

  • February 04, 2026

    Teva Wins 1st Paragard IUD Bellwether Trial

    Teva Pharmaceuticals won a complete defense verdict Tuesday in the first trial testing claims that the company failed to warn consumers that its Paragard IUD has a defect making it prone to breakage inside patients' uteri.

  • February 04, 2026

    Walgreens Says Audio Recording Refutes Shareholders' Claim

    Walgreens told an Illinois federal judge Tuesday that newly discovered evidence warrants revisiting a decision allowing shareholders' claim over an executive's allegedly false statement to move forward, saying an audio recording shows "no basis to conclude the actual statement was false or misleading when made."

  • February 04, 2026

    Teva Fights Class Cert. Bid In Effexor Antitrust Case

    Teva Pharmaceuticals urged a New Jersey federal judge Wednesday to reject a class certification bid by a group of direct buyers of the antidepressant drug Effexor XR and its generic versions, arguing that the proposed class failed to carry its burden showing that joinder is impracticable.

  • February 04, 2026

    Stem-Cell Drug Developer PrimeGen Inks $1.5B SPAC Merger

    Regenerative medicine developer PrimeGen US said Wednesday it has agreed to go public through a merger with blank check company DT Cloud Star Acquisition Corp., in a deal that values the company at about $1.5 billion.

  • February 04, 2026

    Whoop Nabs Block On Chinese Co.'s Health-Tracker Products

    A Massachusetts federal judge has blocked a Chinese company from selling in the U.S. its health-tracking products that were alleged by health band maker Whoop Inc. to be infringing its trade dress.

  • February 04, 2026

    Drugmakers Say Hagens Berman Responsible For Costs

    Drugmakers including GSK and Sanofi have told a Pennsylvania federal court that plaintiffs firm Hagens Berman Sobol Shapiro LLP should bear the costs for the special master tasked with sorting out long-running disputes in a since-dropped product liability suit.

  • February 04, 2026

    Fertility Clinic Says Doctors Lured Staff To New Practice

    The owners of a Massachusetts fertility clinic say three doctors left to start their own practice and repeatedly violated a non-solicitation agreement to "raid" its staff, according to a complaint filed in state court.

Expert Analysis

  • Attys Beware: Generative AI Can Also Hallucinate Metadata

    Author Photo

    In addition to the well-known problem of AI-generated hallucinations in legal documents, AI tools can also hallucinate metadata — threatening the integrity of discovery, the reliability of evidence and the ability to definitively identify the provenance of electronic documents, say attorneys at Law & Forensics.

  • Lessons From Fed. Circ. On Expert Testimony In Patent Cases

    Author Photo

    Several recent decisions from the Federal Circuit are notable for their treatment of expert testimony, with relevance to the three pillars of every patent case — infringement, invalidity and damages — and offer lessons on ensuring that expert testimony is both admissible and sufficient to support the jury's verdict, say attorneys at Honigman.

  • When Atty Ethics Violations Give Rise To Causes Of Action

    Author Photo

    Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.

  • What's New In FDA's Latest Cell And Gene Therapy Guidance

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.

  • Trending At The PTAB: A Potential Barrier To Serial Challenges

    Author Photo

    New rules proposed by the U.S. Patent and Trademark Office may appear similar to previous rules at first glance, but are actually much broader in how they would limit petitioners' ability to challenge a patent more than once, say attorneys at Finnegan.

  • What's Changing For Cos. In New Calif. Hazardous Waste Plan

    Author Photo

    While the latest hazardous waste management plan from California's Department of Toxic Substances Control still awaits final approval, companies can begin aligning internal systems now with the plan's new requirements for environmental justice, waste and disposal reduction, waste criteria, and capacity planning, says Thierry Montoya at Frost Brown.

  • Fed. Circ. In September: The Printed Matter Doctrine Expands

    Author Photo

    The Federal Circuit’s recent decision in Bayer v. Mylan represents an extension of the doctrine that adding new words to an existing product or method will not support patentability unless there is a functional relationship, bringing new considerations for both patent holders and challengers, say attorneys at Knobbe Martens.

  • Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split

    Author Photo

    In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor.

  • Series

    Practicing Stoicism Makes Me A Better Lawyer

    Author Photo

    Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.

  • Broader Eligibility For AI-Related Patents May Be Coming

    Author Photo

    A series of recent developments from the U.S. Patent and Trademark Office appears to signal that claims involving improvement in the operation of a machine learning model are now more likely to be considered patent-eligible, and that patent examiners may focus on questions of novelty and nonobviousness and less so on subject matter eligibility, say attorneys at Kilpatrick.

  • Series

    The Biz Court Digest: Texas, One Year In

    Author Photo

    A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.

  • AI Product Safety Insights May Expand Foreseeability

    Author Photo

    Product liability law has long held that companies are responsible for risks they knew about or should have known about — and with AI systems now able to assess and predict hazards during the design process, companies should expect that courts will likely treat such hazards as foreseeable, says Donald Fountain at Clark Fountain.

  • Series

    Law School's Missed Lessons: Educating Your Community

    Author Photo

    Nearly two decades prosecuting scammers and elder fraud taught me that proactively educating the public about the risks they face and the rights they possess is essential to building trust within our communities, empowering otherwise vulnerable citizens and preventing wrongdoers from gaining a foothold, says Roger Handberg at GrayRobinson.

  • Organ Transplant System Reforms Mark Regulatory Overhaul

    Author Photo

    Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render.

  • Adapting To USPTO's Reduction Of Examiner Interview Time

    Author Photo

    Reported changes to the U.S. Patent and Trademark Office's examiner performance appraisal plan will likely make interviews scarcer throughout the application process, potentially influencing patent allowance rates and increasing the importance of approaching each interview with a clear agenda and well-defined goals, say attorneys at Polsinelli.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.